Replay available

hVIVO plc (HVO) Q4 2025 Earnings Call

hVIVO plc (LSE: HVO) Q4 2025 earnings conference call, held 2026-04-15. Replay captured from the company's public earnings webcast.

Wed, April 15, 2026 at 1:00 PMendedReplay
hVIVO plc (HVO) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Steven Pinkerton

Chief Financial Officer

Yami Moukan

Chief Executive Officer

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the HVIVO Annual Results Investor Presentation. Throughout today's recorded meeting, you'll be in listen-only mode. Questions are encouraged. Please submit them at any time, just using that Q&A tab on the right-hand corner of your screen. Just simply type in your question and press send. Before we begin, we'd like to submit the following poll, and please do give that your attention. I'm sure the company will be most grateful. I'd now like to hand over to CEO and CFO, Mo Stephen. Good afternoon. Good afternoon. Thank you for the for the intro. So I'm Yami Moukan. I'm the CEO of HFEVO. I've been with the company for just over four years and I have with me our CFO, Steven. Hi, I'm Steven Pinkerton. I've been with the company for almost nine years. I've been CFO for the last four years. I would like to welcome you all to our full year 2025 results. The company has had a challenging 2025, at least financially, but operationally, I think we've done some great work and we'll go through both our operational achievements as well as our key financial parameters. So we'll straight on to the financial, the normal disclaimer, and then really to go through the company's overview of what we are planning to do from a strategy point of view and what we have achieved. Because it's key to have a strategy, of course it is, but it's also key to see how we are progressing in executing that strategy. As you all know, we are the world leader in human challenge trials, and we will remain so, and we are continuing working hard to expand our human challenge trial capabilities. But one of our key focus area is to continue to diversify and add new capability. And that's been part of our action for the whole of 2025 and 2026. we'll really talk ...

More from Hvivo Plc